FDA-Approved Treatments for Coronary Artery Disease (CAD): What to Know

CAD is usually the result of plaque buildup that narrows the coronary arteries and limits blood flow to the heart muscle. Treatment focuses on reducing symptoms like chest discomfort (angina), preventing blood clots, lowering cholesterol, controlling blood pressure, and decreasing the chance of heart attack or other complications. In the United States, many commonly prescribed therapies are FDA-approved for specific cardiovascular indications, and they are often used together as part of a long-term plan.

This article is for informational purposes only and should not be considered medical advice. Please consult a qualified healthcare professional for personalized guidance and treatment.

FDA approved CAD medications: key categories

FDA approved CAD medications generally fall into a few core groups, each targeting a different risk pathway. Antiplatelet medicines reduce the tendency of blood to clot on top of plaque; aspirin is widely used, and other antiplatelets such as clopidogrel, prasugrel, or ticagrelor may be prescribed after a stent or for certain higher-risk situations. Anticoagulants are different from antiplatelets and may be used when CAD coexists with conditions like atrial fibrillation, where stroke prevention is the priority.

Cholesterol-lowering therapy is another cornerstone. Statins such as atorvastatin or rosuvastatin are commonly used because lowering LDL cholesterol reduces cardiovascular risk over time. When additional LDL lowering is needed, clinicians may add non-statin options such as ezetimibe, or consider injectable PCSK9 inhibitors like alirocumab or evolocumab for selected patients.

Symptom control often involves antianginal drugs. Short-acting nitroglycerin can relieve acute chest tightness, while longer-acting nitrates, beta blockers (such as metoprolol), and calcium channel blockers (such as amlodipine or diltiazem) may reduce the frequency of angina. Another option, ranolazine, may be used when symptoms persist despite other therapies. Which combination is appropriate depends on factors such as heart rate, blood pressure, other medical conditions, and medication tolerance.

Heart disease treatment options beyond medication

Heart disease treatment options for CAD extend well beyond pills, and many plans start with risk-factor management. Clinicians commonly emphasize tobacco cessation, a heart-healthy eating pattern, regular physical activity appropriate to a person’s condition, weight management, and sleep and stress support. Cardiac rehabilitation, when available through local services, can be especially helpful because it combines supervised exercise, education, and risk-reduction coaching in a structured program.

For people with persistent symptoms, high-risk test results, or certain types of blockages, procedures may be considered. Percutaneous coronary intervention (PCI) uses balloon angioplasty and typically places a stent to keep an artery open. Many stents used today are drug-eluting stents, which release medication locally to reduce the risk of re-narrowing. Coronary artery bypass grafting (CABG) is a surgical option for more complex disease patterns, such as left main disease or multivessel CAD in some patients. These decisions are individualized and usually guided by symptoms, imaging results, anatomy, and overall health.

Ongoing monitoring is also part of care. Blood pressure checks, cholesterol testing, diabetes screening, and periodic review of symptoms help clinicians adjust therapy. In some cases, additional testing (such as stress testing, coronary CT angiography, or cardiac catheterization) is used to clarify risk or guide next steps, particularly when symptoms change.

Cardiovascular medications: safety and questions to discuss

Cardiovascular medications can be highly effective, but safety depends on using the right drug at the right dose for the right person. Side effects vary by class: antiplatelets can increase bleeding risk; statins can cause muscle symptoms in some people; beta blockers may slow heart rate and can worsen fatigue for certain patients; and nitrates may trigger headaches or low blood pressure. Some combinations require extra caution, such as avoiding certain erectile dysfunction medicines with nitrates due to the risk of a dangerous blood pressure drop.

A practical way to think about medication decisions is to separate them into two goals: risk reduction and symptom relief. Risk-reduction medicines (like statins and antiplatelets when indicated) are usually taken long term, even if you feel well. Symptom-relief medicines (like nitroglycerin or some antianginals) are often adjusted based on how frequently angina occurs and what triggers it. Adherence matters, so it is reasonable to ask about simplified dosing, affordability, and what to do if a dose is missed.

It also helps to review the full medication list at each visit, including over-the-counter products and supplements. Some supplements can interact with prescription drugs or affect bleeding risk. If you have kidney disease, liver disease, a history of bleeding, or you are planning surgery or dental procedures, those details can change which medicines are safest. Shared decision-making is especially important when balancing benefits (such as fewer cardiac events over time) against individual risks.

CAD treatment is usually most successful when it combines FDA-approved therapies with sustained risk-factor control and regular follow-up. Medications may address clotting risk, cholesterol levels, blood pressure, and angina symptoms, while procedures like PCI or bypass surgery may be appropriate for selected patterns of disease. Because CAD varies widely from person to person, the most appropriate plan is the one tailored to your symptoms, anatomy, and overall risk profile by a qualified clinician.